Introduction
Introduction
Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) in combination with Jevtana (cabazitaxel; Sanofi) as a second-line treatment for metastatic castrate-resistant PC (mCRPC), and the development of Lynparza (olaparib; AstraZeneca) as a treatment for BRCA1/2 or ATM gene mutated mCRPC in patients who have received prior taxane-based chemotherapy and Zytiga (abiraterone acetate; Johnson & Johnson), or Xtandi (enzalutamide; Astellas/Medivation). The UK’s National Institute for Health and Clinical Excellence’s (NICE) recommendations concerning the use of Xtandi and Zytiga for treating mCRPC in a pre-chemotherapy setting are also discussed.
Key Questions Answered in this Update Bulletin:
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Table of Contents
for Prostate Cancer: Update Bulletin [Feb 2016] [Published by FirstWord Pharma]
Additional Details
Publisher
FirstWord Pharma
Publisher Information
Reference
302 |
Report Format
Related Reports
| Title | Date Published | Price from | More Details |
|---|---|---|---|
| SAVE 15% today! Global Prostate Cancer Partnering 2010 to 2016 The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce... | 01 Oct 2016 by Current Partnering | USD $1,271 (normally USD $1,495) |
More Info |
| SAVE 15% today! Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Tria... | 15 Jun 2016 by Global Data | USD $2,125 (normally USD $2,500) |
More Info |
| SAVE 15% today! Vancouver Prostate Centre - Pharmaceuticals & Healthcare - Deals and Alliances Profile SummaryVancouver Prostate Centre (Vancouver Prostate) is a cancer research center that conducts rese... | 13 May 2016 by Global Data | USD $213 (normally USD $251) |
More Info |
| SAVE 15% today! Vancouver Prostate Centre - Pharmaceuticals & Healthcare - Deals and Alliances Profile SummaryVancouver Prostate Centre (Vancouver Prostate) is a cancer research center that conducts rese... | 17 Mar 2016 by Global Data | USD $213 (normally USD $251) |
More Info |
| SAVE 15% today! Prostate Cancer: KOL Insight IntroductionThe last decade has seen significant change in how prostate cancer is treated. Innovatio... | 01 Nov 2015 by FirstWord Pharma | USD $6,715 (normally USD $7,900) |
More Info |
| SAVE 15% today! Physician Views: Can Astellas, Medivation's Xtandi meet expectations in pre-chemotherapy prostate cancer? Scope Having secured approval for the treatment of pre-chemotherapy prostate cancer patients earlier... | 25 Sep 2014 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
| SAVE 15% today! Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market? Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget... | 01 Dec 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
| SAVE 15% today! KOL Insight: Prostate Cancer: Competition intensifies in race to the top IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The... | 01 Nov 2013 by FirstWord Pharma | USD $6,715 (normally USD $7,900) |
More Info |
| SAVE 15% today! Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper... | 01 Nov 2013 by FirstWord Pharma | USD $4,246 (normally USD $4,995) |
More Info |
| SAVE 15% today! Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting? ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi... | 01 Oct 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
This report is published by FirstWord Pharma
Download Free Report Summary PDF
![Prostate Cancer: Update Bulletin [Feb 2016] [Published by FirstWord Pharma] | Download PDF Summary](img/xpdf-summary.jpg.pagespeed.ic.PvEUQqtmCi.jpg "Prostate Cancer: Update Bulletin [Feb 2016] [Published by FirstWord Pharma] | Download PDF Summary")
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Ordering Information
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.